The US FDA has approved, on Monday Pembrolizumab in combination with carboplatin and paclitaxel, followed by pembrolizumab as a single agent, to treat adult patients with primary, advanced or recurrent endometrial carcinoma.
The approval came after considering data from the phase 3 NRG-GY018 trial (NCT03914612). During tests, it was found that the Pembrolizumab combination reduced disease progression or death compared with Pembrolizumab administered alone.
Endometrial cancer is believed to be the most common gynaecologic cancer in the US. The anti-programmed death receptor-1 (PD-1) therapy works by increasing the immune system's ability to detect and fight tumour cells.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval